Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.
USOR 24215 - Ph2 Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens
A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Disease Types: Lung - Non-Small Cell Lung
Available at: Arlington Heights, Chicago, Niles